Clinical trial
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or…
NCT02257567 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02257567 |
|---|---|
| Title | A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma |
| Official title | A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid), Rituximab, Polatuzumab vedotin (Lyophilized) |
| Enrollment | 331 |
| Start date | Oct 15, 2014 |
| Primary completion | Oct 21, 2021 |
| Completion | Oct 21, 2021 |
| First posted | Oct 6, 2014 |
| Last update posted | Nov 14, 2022 |
| Countries | Australia, Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, South Korea, Spain, Turkey (Türkiye), United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: